Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul;46(suppl.1):125-132.
doi: 10.1590/S1677-5538.IBJU.2020.S118.

Treatment and research lines for the patient with COVID-19. What do we have and where are we going?

Carolina Gotera  1
Affiliations
Review

Treatment and research lines for the patient with COVID-19. What do we have and where are we going?

Carolina Gotera. Int Braz J Urol. 2020 Jul.

Abstract

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents the most significant global public health crisis of this generation. From the beginning of the pandemic, several publications and on-line resources about different treatment lines have been done, and development effort in response to the COVID-19 pandemic to investigate potential therapies is unprecedented. Unfortunately, until now, there is not enough evidence to recommend any specific anti-COVID19 treatment. Randomized clinical trials and high-quality evidence, even in the middle of a pandemic, are needed. We provide a review of the latest published literature on the therapeutic strategies and current investigational lines for SARS-CoV-2.

Keywords: COVID-19 diagnostic testing [Supplementary Concept]; Patients; Therapeutics.

PubMed Disclaimer

Conflict of interest statement

None declared.

Comment in

References

    1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708–1720. - PMC - PubMed
    2. 1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-20. - PMC - PubMed
    1. Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26:681–687. - PMC - PubMed
    2. 2. Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020; 26:681-7. - PMC - PubMed
    1. Coronavirus Resource Center. Johns Hopkins University; [No Authors] [Internet]. Available at. < https://coronavirus.jhu.edu/map.html>.
    2. 3. [No authors]. Coronavirus Resource Center. Johns Hopkins University. [Internet]. Available at. <https://coronavirus.jhu.edu/map.html>.
    1. Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020;250:117583–117583. - PMC - PubMed
    2. 4. Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020; 250:117583. - PMC - PubMed
    1. AminJafari A, Ghasemi S. The possible of immunotherapy for COVID-19: A systematic review. Int Immunopharmacol. 2020;83:106455–106455. - PMC - PubMed
    2. 5. AminJafari A, Ghasemi S. The possible of immunotherapy for COVID-19: A systematic review. Int Immunopharmacol. 2020; 83:106455. - PMC - PubMed